Macrogenics Inc (MGNX) reports a remarkable revenue increase driven by milestone payments, while navigating leadership ...

Capital Performance Advisors LLP bought a new position in Incyte Co. (NASDAQ:INCY – Free Report) in the third quarter, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Syndax Pharmaceuticals announces positive Phase 2 trial results for revumenib in relapsed/refractory mNPM1 AML, with key ...

Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 33,003 shares of the Company’s common stock and stock option awards to purchase an ...

On Friday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $83.38 which represents a slight increase of $1.04 or 1.26% from the prior close of $82.34. The stock opened at $82.59 and ...

New real-world data from Providence, Illumina (NASDAQ: ILMN), and Microsoft Research reveals that Comprehensive Genomic Profiling (CGP), when done early in a cancer patient’s diagnosis, leads to ...

A US district court has granted an injunction sought by Incyte on the launch of Sun Pharma's recently approved Leqselvi for alopecia areata. In a brief filing with the National Stock Exchange (NSE ...

Wealth Enhancement Advisory Services LLC grew its position in Incyte Co. (NASDAQ:INCY – Free Report) by 22.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,533 shares of ...

Incyte and MorphoSys' antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative to expensive and cumbersome CAR-T therapies for patients with ...

Willey covers the Healthcare sector, focusing on stocks such as Zymeworks, Exelixis, and Incyte. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Geron with a ...